Application and Study Protocol Accepted for BPH Drug
Spectrum Pharmaceuticals, Inc., of Irvine, Calif., has announced the FDA’s acceptance of its Investigational New Drug application for ozarelix for the treatment of benign prostatic hyperplasia (BPH) and approval of a phase IIb study of the drug.
The e-mail address(es) that you supply to use this service will only be used to send the requested article.